奥妥珠单抗治疗滤泡性淋巴瘤的研究进展  

Research progress on obinutuzumab in treatment of follicular lymphoma

作　　者：冷婉铜 陶洁[1] Leng Wantong;Tao Jie(Department of Hematology,First Hospital of Shanxi Medical University,Taiyuan 030001,Shanxi Province,China)

机构地区：[1]山西医科大学第一临床医学院血液科,太原030001

出　　处：《国际输血及血液学杂志》2022年第3期273-276,F0003,共5页International Journal of Blood Transfusion and Hematology

摘　　要：滤泡性淋巴瘤(FL)是常见惰性非霍奇金淋巴瘤(NHL)亚型之一。随着对FL靶向治疗研究的深入,Ⅰ型CD20单克隆抗体利妥昔单抗联合化疗作为FL患者的一线治疗方案在临床中广泛应用,使患者的生存率显著提升,但是仍有部分患者由于耐药或者治疗相关不良发应,出现复发或者疾病进展。奥妥珠单抗是首个人源化Ⅱ型糖基化工程CD20单克隆抗体,可单独或者联合其他药物应用于初治或者复发/难治性FL患者。与利妥昔单抗相比,奥妥珠单抗的抗FL活性良好,可延长患者的生存期,并且患者耐受性良好。采取奥妥珠单抗治疗FL常见的不良反应包括输注相关反应(IRR)、血细胞减少等。笔者拟就奥妥珠单抗治疗FL的作用机制、用药方案、临床疗效及不良反应等新研究进展进行综述,旨在为奥妥珠单抗临床治疗FL患者提供参考。Follicular lymphoma(FL)is one of common subtypes of indolent non-Hodgkin lymphoma(NHL).With further study of targeted therapy,typeⅠanti-CD20 monoclonal antibody,rituximab combined with chemotherapy has been widely used in clinical practice as the first-line treatment for patients with FL,which improved the survival rate of FL patients significantly.But there are still some patients have drug resistance or adverse reactions,and relapse or progressive disease.Obinutuzumab,the first human-derived typeⅡglycosylation-engineered anti-CD20 monoclonal antibody,can be used alone or in combination with other agents in patients with newly diagnosed or relapsed/refractory FL.Compared with rituximab,obinutuzumab can prolong survival time of FL patients,has good antitumor activity and is well tolerated by patients.Common adverse reactions of obinutuzumab in treatment of FL include infusion-related reactions(IRR)and cytopenia.In order to provide reference for the clinical treatment of FL patients with obinutuzumab,this article reviews the research advances in mechanisms of action,medication regimens,clinical efficacy and adverse reactions of obinutuzumab in FL treatment.

关 键 词：淋巴瘤 滤泡性 抗原 CD20 抗体 单克隆 药物治疗 奥妥珠单抗 

分 类 号：R733.1[医药卫生—肿瘤]